HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stroop, S. D. Articles by Beavo, J. A. Search for Related Content PubMed PubMed Citation Articles by Stroop, S. D. Articles by Beavo, J. A. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 266, Issue 35, 23802-23809, Dec, 1991

Structure and function studies of the cGMP-stimulated phosphodiesterase

SD Stroop and JA Beavo
Department of Pharmacology, University of Washington, Seattle 98195.

Studies of cGMP binding to both the native cyclic GMP-stimulated phosphodiesterase and to two unique isolated chymotryptic fragments lacking the catalytic domain suggest that the enzyme contains two noncatalytic cGMP-binding sites/homodimer. In the presence of high concentrations of ammonium sulfate, 2 mol of cGMP are bound/mol of cGMP- stimulated phosphodiesterase homodimer. Under these conditions, linear Scatchard plots of binding are obtained that give an apparent Kd of approximately 2 microM. The inclusion of 3-isobutyl-1-methylxanthine produces a curvilinear plot. In the absence of ammonium sulfate, the dissociation of cGMP from the holoenzyme is rapid, having a t1/2 of less than 10 s, and addition of ammonium sulfate to the incubation greatly decreases this rate of dissociation. The native enzyme is resistant to degradation by chymotrypsin in the absence of cGMP; however, in its presence, chymotrypsin treatment produces several discrete fragments. Similarly, in the presence but not in the absence of cGMP, dicyclohexylcarbodiimide causes an irreversible activation of the enzyme without cross-linking the nucleotide to the phosphodiesterase. Both observations provide evidence that a different conformation in the enzyme results from cGMP binding. Only the conformation formed upon cGMP binding is easily attacked by chymotrypsin or permanently activated by treatment with dicyclohexylcarbodiimide. One major chymotryptic cleavage site exposed by cGMP binding is at tyrosine 553, implying that this region takes part in the conformational change. Limited proteolysis experiments indicate that these noncatalytic binding sites are located within a region of internal sequence homology previously proposed to include the cGMP-binding site(s) and that they retain a high affinity and specificity for cGMP independent of the catalytic domain of the enzyme. The products formed by partial proteolysis can be separated into individual catalytically active and cGMP-binding fractions by anion exchange chromatography. Gel filtration and electrophoresis analysis of the isolated fractions suggest that the cGMP-binding peak has a dimeric structure. Moreover, it can be further resolved by polyethyleneimine high performance liquid chromatography into two peaks (Peaks IIIA and IIIB). Peak IIIA binds 2 mol of cGMP/mol of dimer with an apparent Kd of 0.2 microM. Peak IIIB, however, has greatly reduced cGMP binding. Further digestion of these fragments with cyanogen bromide show that the differences between Peaks IIIA and IIIB are due to one or more additional proteolytic nicks in IIIB that remove a few residues near its C terminus, most probably residues 523-550 or 534-550. This in turn suggests that this region is essential for cGMP-binding activity.(ABSTRACT TRUNCATED AT 400 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. C. Heikaus, J. R. Stout, M. R. Sekharan, C. M. Eakin, P. Rajagopal, P. S. Brzovic, J. A. Beavo, and R. E. Klevit Solution Structure of the cGMP Binding GAF Domain from Phosphodiesterase 5: INSIGHTS INTO NUCLEOTIDE SPECIFICITY, DIMERIZATION, AND cGMP-DEPENDENT CONFORMATIONAL CHANGE J. Biol. Chem., August 15, 2008; 283(33): 22749 - 22759. [Abstract] [Full Text] [PDF]

				M. A. Blount, R. Zoraghi, E. P. Bessay, A. Beasley, S. H. Francis, and J. D. Corbin Conversion of Phosphodiesterase-5 (PDE5) Catalytic Site to Higher Affinity by PDE5 Inhibitors J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 730 - 737. [Abstract] [Full Text] [PDF]

				L.-W. Guo, H. Muradov, A. R. Hajipour, M. K. Sievert, N. O. Artemyev, and A. E. Ruoho The Inhibitory {gamma} Subunit of the Rod cGMP Phosphodiesterase Binds the Catalytic Subunits in an Extended Linear Structure J. Biol. Chem., June 2, 2006; 281(22): 15412 - 15422. [Abstract] [Full Text] [PDF]

				R. Zoraghi, E. P. Bessay, J. D. Corbin, and S. H. Francis Structural and Functional Features in Human PDE5A1 Regulatory Domain That Provide for Allosteric cGMP Binding, Dimerization, and Regulation J. Biol. Chem., March 25, 2005; 280(12): 12051 - 12063. [Abstract] [Full Text] [PDF]

				S. Laxman, A. Rascon, and J. A. Beavo Trypanosome Cyclic Nucleotide Phosphodiesterase 2B Binds cAMP through Its GAF-A Domain J. Biol. Chem., February 4, 2005; 280(5): 3771 - 3779. [Abstract] [Full Text] [PDF]

				A. Y. Wu, X.-B. Tang, S. E. Martinez, K. Ikeda, and J. A. Beavo Molecular Determinants for Cyclic Nucleotide Binding to the Regulatory Domains of Phosphodiesterase 2A J. Biol. Chem., September 3, 2004; 279(36): 37928 - 37938. [Abstract] [Full Text] [PDF]

				J. D. Corbin, M. A. Blount, J. L. Weeks II, A. Beasley, K. P. Kuhn, Y. S. J. Ho, L. F. Saidi, J. H. Hurley, J. Kotera, and S. H. Francis [3H]Sildenafil Binding to Phosphodiesterase-5 Is Specific, Kinetically Heterogeneous, and Stimulated by cGMP Mol. Pharmacol., June 1, 2003; 63(6): 1364 - 1372. [Abstract] [Full Text] [PDF]

				K. G. Muradov, K. K. Boyd, S. E. Martinez, J. A. Beavo, and N. O. Artemyev The GAFa Domains of Rod cGMP-phosphodiesterase 6 Determine the Selectivity of the Enzyme Dimerization J. Biol. Chem., March 14, 2003; 278(12): 10594 - 10601. [Abstract] [Full Text] [PDF]

				S. H. Francis, E. P. Bessay, J. Kotera, K. A. Grimes, L. Liu, W. J. Thompson, and J. D. Corbin Phosphorylation of Isolated Human Phosphodiesterase-5 Regulatory Domain Induces an Apparent Conformational Change and Increases cGMP Binding Affinity J. Biol. Chem., November 27, 2002; 277(49): 47581 - 47587. [Abstract] [Full Text] [PDF]

				S. E. Martinez, A. Y. Wu, N. A. Glavas, X.-B. Tang, S. Turley, W. G. J. Hol, and J. A. Beavo The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding PNAS, October 1, 2002; 99(20): 13260 - 13265. [Abstract] [Full Text] [PDF]

				C. F. Plato {alpha}-2 And {beta}-adrenergic receptors mediate NE's biphasic effects on rat thick ascending limb chloride flux Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R979 - R986. [Abstract] [Full Text] [PDF]

				P. A. Ortiz and J. L. Garvin NO Inhibits NaCl Absorption by Rat Thick Ascending Limb Through Activation of cGMP-Stimulated Phosphodiesterase Hypertension, February 1, 2001; 37(2): 467 - 471. [Abstract] [Full Text] [PDF]

				A. E. Granovsky, M. Natochin, R. L. McEntaffer, T. L. Haik, S. H. Francis, J. D. Corbin, and N. O. Artemyev Probing Domain Functions of Chimeric PDE6alpha '/PDE5 cGMP-Phosphodiesterase J. Biol. Chem., September 18, 1998; 273(38): 24485 - 24490. [Abstract] [Full Text] [PDF]

				N. O. Artemyev, R. Surendran, J. C. Lee, and H. E. Hamm Subunit Structure of Rod cGMP-Phosphodiesterase J. Biol. Chem., October 11, 1996; 271(41): 25382 - 25388. [Abstract] [Full Text] [PDF]

				M. Natochin and N. O. Artemyev An Interface of Interaction between Photoreceptor cGMP Phosphodiesterase Catalytic Subunits and Inhibitory gamma Subunits J. Biol. Chem., August 16, 1996; 271(33): 19964 - 19969. [Abstract] [Full Text] [PDF]